Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250013/S002

aura6000 system

LivaNova USA, Inc. · Decision date Jun 18, 2026

FDA DECISIONP250013/S002

What did the FDA approve?

FDA records P250013/S002 as a supplement to PMA P250013, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jun 18, 2026.

FDA approval order statement

approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250013
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Anesthesiology
Decision date
Jun 18, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P250013/S002
Regulatory pathway
PMA supplement
Product code
MNQ
Decision code
APPR
Decision date
Jun 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.

Product code
MNQ
FDA device class
3

For the original device and its historical approval scope, see PMA P250013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250013/S002 received

    Application receipt date recorded by FDA.

  2. P250013/S002 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P250013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250013

Product / regulatory recordCompanyPathwayDecision dateSource
LivaNova USA, Inc.PMA approvalMar 18, 2026FDA
aura6000 systemP250013/S001
LivaNova USA, Inc.PMA supplementApr 30, 2026FDA

Explore the linked device profile

Other records with product code MNQ

Product / regulatory recordCompanyPathwayDecision dateSource
Inspire Medical SystemsPMA supplementNov 5, 2026FDA
Inspire Medical SystemsPMA supplementOct 26, 2026FDA
Model 3150 IPGP130008/S147
Inspire Medical SystemsPMA supplementOct 22, 2026FDA
Model 3150 IPGP130008/S146
Inspire Medical SystemsPMA supplementOct 13, 2026FDA
Inspire Medical SystemsPMA supplementAug 28, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LivaNova USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Cyberonics Blvd., Houston, TX, 77058

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records